LeeSRosenMD
Hematology • Santa Monica, CAMyeloproliferative Disorder Hematology-Oncology
Professor, Medicine, University of California Los Angeles David Geffen SOM
Dr. Rosen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd
Ste 510
Santa Monica, CA 90404Phone+1 310-633-8400Fax+1 310-633-8419
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
Baylor College of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1991 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2011
- Super Doctor SuperDoctors.com
Clinical Trials
- Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer Start of enrollment: 2001 Apr 01
- Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2000 Dec 01
- Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2001 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical st...Danny N Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey
Investigational New Drugs. 2023-06-01 - 5 citationsA tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.Danny N Khalil, Isabel Prieto González-Albo, Lee Rosen, Tom Lillie, Andrea Stacey
Investigational New Drugs. 2023-04-01 - 36 citationsEfficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.Alexander Drilon, Daniel S W Tan, Ulrik N Lassen, Serge Leyvraz, Yongmei Liu
JCO Precision Oncology. 2022-01-01
Professional Memberships
- Fellow
- Member
- Member
- Member
Other Languages
- Hebrew, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
